TIMD4 and glioma: Notably, monoclonal antibodies targeting TIM‐4 inhibit the phagocytic activity of TIM‐4+ peritoneal macrophages.[94] Interestingly, TIM‐4 protein exhibits close associations with human malignancies and is markedly overexpressed in malignant tissues like ovarian cancer,[103] glioma,[104] and nonsmall cell lung cancer (NSCLC).[99] Its involvement in disease recurrence, metastasis, EMT, and its correlation with clinical staging, pathological grading, and cancer prognosis have been well‐documented.